Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Xiaoxuan GongRui HuaJianling BaiTianyu WuQin WangJin-Hua ZhangWenhao ZhangLianghong YingYongsheng KeXiaoyan WangXiwen ZhangKun LiuYan ChenBoqing ZhangPeng DongJianqiang XiaoChangling LiLi ZhuChunjian LiPublished in: Clinical cardiology (2023)
The OPTIMA-4 trial offers an opportunity to assess the optimal dual antithrombotic regimen in ACS patients with concomitant NVAF after the implantation of new-generation DES.
Keyphrases
- atrial fibrillation
- acute coronary syndrome
- percutaneous coronary intervention
- phase iii
- study protocol
- oral anticoagulants
- left atrial
- direct oral anticoagulants
- clinical trial
- phase ii
- catheter ablation
- left atrial appendage
- heart failure
- open label
- left ventricular
- combination therapy
- placebo controlled
- double blind